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A B S T R A C T   
The available pharmacological modalities for the treatment of fibromyalgia (FM) are associated with a variety of 
adverse effects and limited benefits. In this study, we systematically reviewed the impact of melatonin in the 
treatment of FM. Interventional studies, either controlled or uncontrolled and randomized or non-randomized, 
were included. PubMed, EMBASE, Scopus, Web of Science, and the Cochrane Library were searched without 
time limitation. Primary outcome measures were the effect of melatonin on the disease impact, pain, sleep 
quality, tender point count, fatigue, anxiety, stiffness, and depression in FM patients. Four studies, reporting the 
effect of melatonin on 98 patients, were eligible to include. All the studies reported the positive effect of 
melatonin on the FM symptoms. No major adverse event was reported. A significant level of heterogeneity was 
observed between the studies. Therefore, further high-quality controlled clinical trials are needed to understand 
the role of melatonin in FM treatment fully.   
1. Introduction 
Melatonin is an essential hormone of the pineal gland with pleio-
tropic activity. Many extra-pineal organs have also been identified as the 
melatonin producers, such as skeletal muscles, gastrointestinal tract, 
immune system cells, liver, spleen, kidney, retina, and heart [1,2]. A 
wide range of physiological and metabolic functions have been reported 
for melatonin. In addition to the analgesic, antioxidant, and 
anti-inflammatory effects, melatonin regulates the circadian biology, 
cellular autophagy, immune system, body temperature, and reproduc-
tion [3]. The role of melatonin in a variety of human diseases such as 
cancers, mental disorders, cardiovascular disorders, intestinal disorders, 
retinal disorders, renal disorders, musculoskeletal disorders, and meta-
bolic disorders has been demonstrated [4–7]. Melatonin also has a 
protective effect against obesity, diabetes, sepsis, and fibrosis, and 
significantly improves sleep quality, fatigue, anxiety, and depression [5, 
8,9]. An anti-nociceptive role has proposed for melatonin as well, 
although still controversial [10]. Considering the versatile and multi-
functional effects of melatonin and its role in different clinical 
conditions, it has been described as the “miracle far beyond the pineal 
gland” [11]. 
Fibromyalgia (FM) is one of the most prevalent debilitating condi-
tions characterized by chronic and widespread pain, tenderness, and 
functional symptoms [12–14]. The global prevalence of FM is estimated 
to be 2.7%, ranging from 0.4% in Greece [15] to 9.3% in Tunisia [16]. 
The mean prevalence is estimated by 3.1% in the Americas, 2.5% in 
Europe, and 1.7% in Asia [17]. FM is associated with sleep disorders, 
fatigue, anxiety, and depression [18]. Recent evidence suggests the 
involvement of oxidative stress and inflammatory cytokines in the 
pathogenesis of FM [14,19,20]. The nociceptive aspects of FM have also 
been discussed in various investigations [21,22]. 
Connecting the physiologic & metabolic functions of melatonin with 
the pathogenesis & clinical manifestations of FM proposes an underlying 
role for melatonin in the etiopathology of FM. Recently, it was discov-
ered that mitochondria are a potent melatonin producer [23]. Since 
muscles contain a large number of mitochondria, mitochondrial 
dysfunction could result in low melatonin production that may have 
some associations with fibromyalgia [24]. In support of this role, the 
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study of Pernambuco et al. revealed a significantly lower levels of 6-sul-
phatoxymelatonin, as the main metabolite of melatonin, in the urine of 
FM patients in comparison with healthy controls [25]. Consequently, the 
melatonin effect for the treatment of FM was examined in some in-
vestigations. Yet, there is no consensus regarding the potential and the 
effect size of melatonin in the treatment of FM symptoms. 
In this study, we aim to perform a systematic review of the clinical 
trials, either controlled or uncontrolled, that evaluated the effect of 
melatonin in the treatment of FM symptoms, including disease impact, 
pain, tender point count, sleep quality, fatigue, anxiety, and depression. 
To the best of our knowledge, no systematic review has been earlier 
performed on this subject. 
2. Methods 
2.1. Protocol and registration 
This systematic review was designed based on the guidelines of the 
PRISMA statement [26]. The objectives, methods of the analysis, and 
inclusion criteria of this study were specified in advance, and the pro-
tocol was documented in www.crd.york.ac.uk/PROSPERO/under the 
code of CRD42018096903. 
2.2. Eligibility criteria 
Interventional studies, either controlled or uncontrolled and ran-
domized or non-randomized, evaluating the efficacy of melatonin in the 
treatment of fibromyalgia were included. The inclusion criteria were: 1) 
interventional studies (controlled or uncontrolled) on the effect of 
melatonin in the treatment of FM; 2) conducted in adult humans; 3) 
studies in which melatonin treatment was the only therapeutic inter-
vention; 4) studies with quantitative data. The exclusion criteria were: 
1) studies without the outcome of interest; 2) studies in a language other 
than English; 3) and studies that their full-text was not available. The 
study was not restricted by the gender or the age of the patients. 
2.3. Information sources 
Database including PubMed, EMBASE, Scopus, Web of Science, and 
the Cochrane Library were searched without time limitation for English- 
language reports concerning the evaluation of the effect of melatonin in 
the treatment of FM. References of published original articles and re-
views were searched as well. 
2.4. Search 
Melatonin,N-acetyl-5-methoxy tryptamine, and fibromyalgia were 
used as MeSH terms as follows: [(fibromyalgia) and ((melatonin) OR N- 
acetyl-5-methoxy tryptamine)]. 
2.5. Study selection and data extraction 
Two investigators (A.M and A.A.K) reviewed titles and abstracts of 
all identified studies to decide whether the studies are eligible for this 
systematic review or not. Data were extracted from the eligible papers, 
including domains of study characteristics such as the first author’s 
name, study location, year of publication, the sample size in each group, 
population, details of melatonin administration, dosage, and duration. 
The data extraction form was independently completed by two re-
viewers (A.M and F.S) and checked for discrepancies. If present, the 
discrepancies were resolved through discussion to achieve a consensus. 
2.6. Criteria for considering studies 
Types of participants: The study participants were not limited by 
age, gender, and disease impact so that patients with any gender, age, 
and disease impact were included. 
Types of interventions: Clinical trials that exclusively evaluated the 
effect of melatonin on the treatment of FM patients were included. In 
studies that melatonin effect was evaluated both alone and adjunct to 
other FM drugs, only the melatonin alone group were included. 
Types of Comparator/control: The studies were not limited by the 
absence or presence of comparator/control, and all interventional 
studies, either controlled or uncontrolled, were included. The type of 
control could be a placebo or no treatment group, but not other usual 
treatments. 
2.7. Types of outcome measures 
Primary outcome: Primary outcome measures were the effect of 
melatonin on the disease impact, pain, sleep quality, tender point count, 
fatigue, anxiety, stiffness, and depression of FM patients. 
Secondary outcome: The 6-sulfatoxymelatonin (aMT6-s) level, as 
the main urinary metabolite of melatonin, was considered as the sec-
ondary outcome measure. 
2.8. Risk of bias in studies 
The quality of included studies and risk of bias was evaluated by 
Cochrane Risk of Bias Tool (RevMan 5.3.3software) that assesses the 
quality of study in six categories including 1) random sequence gener-
ation (selection bias); 2) allocation concealment (selection bias); 3) 
blinding of participants and personnel (performance bias); 4) blinding of 
outcome assessment (detection bias); 5) incomplete outcome data 
(attrition bias); and 6) other bias [27]. Accordingly, the quality was 
judged into three categories of “high”, “low” and “unclear” risk of bias. 
3. Results 
Out of 224 screened studies, four studies were identified as eligible to 
include in this review. The flowchart of the study is demonstrated in 
Fig. 1. The study design was open [28] in one study and 
placebo-controlled trial in the others [29–31]. In two of the 
placebo-controlled trials, the effect of melatonin alone was compared 
with melatonin as an adjunct to other therapeutic agents such as 
fluoxetine [31] and amitriptyline [29]. Accordingly, there was no 
Fig. 1. Flow diagram of the study selection procedure.  
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placebo group to control the effect of melatonin alone in these studies. 
Therefore, the effect of treatment in melatonin only group (before-after) 
was included in this review. The other placebo-controlled trial was a 
longitudinal study with the administration of five different melatonin 
dose (3, 6, 9, 12, 15 mg) in periods of 10 days each, separated by 
washout periods (10 days each) [30]. The demographic characteristics 
of the included studies are demonstrated in Table 1. 
3.1. The effect of melatonin on the evaluated outcome measures 
The majority of outcome measures were evaluated in three out of 
four studies [28,29,31]. The study of Casta~no et al. only evaluated the 
effect of melatonin on sleep quality and aMT6-s [30]. The types of 
outcome measures evaluated in each study are demonstrated in Table 2. 
3.2. The effect of melatonin on the FM impact 
The effect of melatonin on the FM impact was evaluated in three 
studies [28,29,31]. The patient and physician global assessments were 
used for the assessment of disease impact in the study of Citera et al. 
[28]. Fibromyalgia Impact Questionnaire (FIQ) was used for the eval-
uation of the disease impact in the study of Hussain et al. [31] and de 
Zanette et al. [29]. Citera et al. found a significant improvement in the 
mean patient and physician global assessments score after 28 days of 
treatment of 19 FM patients with 3 mg melatonin at bedtime [28]. 
Hussain et al. observed a significant reduction in both total and different 
components of FIQ score after 60 days of treatment of 27 FM patients 
with 5 mg melatonin at night time [31]. De Zenette et al. also detected a 
significant reduction in the mean FIQ score of 21 FM patients who were 
treated with 10 mg bedtime melatonin for 42 consecutive days. 
3.3. The effect of melatonin on the FM pain 
The effect of melatonin on the pain level of FM patients was evalu-
ated in three studies [28,29,31]. Citera et al. [28] and de Zanette et al. 
[29] used the Visual Analog Scale (VAS) for the assessment of pain. 
Hussain et al. used the pain subset of FIQ as the measure of pain level. 
Citera et al. assessed the severity of pain at the selected points [28], 
while Hussain et al. and de Zanette et al. evaluated the general level of 
pain perceived by the patients [29,31]. All three studies detected a 
significant pain reduction following the melatonin treatment of FM 
patients. 
3.4. The effect of melatonin on the sleep quality of FM patients 
Sleep quality was evaluated as the outcome of interest in all the 
included articles [28–31]. Citera et al. assessed sleep quality using VAS 
and observed a significant improvement after the melatonin adminis-
tration period [28]. Hussain et al. used the rest/sleep subset of FIQ as the 
measure of sleep quality and reported significant improvement 
following the melatonin administration period [31]. De Zanette et al. 
used the Pittsburgh Sleep Quality Index (PSQI) for the assessment of 
sleep quality and revealed a significant improvement after the treatment 
period with melatonin [29]. Casta~no et al. evaluated the sleep quality, 
both subjectively and objectively. The subjective assessment was done 
by the PSQI. Objective assessment was performed with actigraphy. 
Based on their report, subjective sleep quality was improved signifi-
cantly after the administration of 6, 9, 12, and 15 mg melatonin, but not 
after 3 mg melatonin. Moreover, six out of seven objective sleep pa-
rameters were improved after the intake of 12 and 15 mg melatonin, but 
not after 3, 6, and 9 mg melatonin [30]. 
3.5. The effect of melatonin on the tender point count 
The effect of melatonin on the tender point count of FM patients was 
evaluated in the studies of Citera et al. [28] and de Zanette et al. [29]. In 
both studies, the number of tender point count significantly reduced 
after the melatonin administration. 
3.6. The effect of melatonin on the depression level of FM patients 
The effect of melatonin on the depression level of FM patients was 
assessed in three out of four studies [28,29,31]. Citera et al. used VAS for 
the evaluation of depression. They did not find any significant effect of 
melatonin on the depression level of FM patients [28]. Hussain et al. 
used the depression subset of FIQ for the evaluation of the melatonin 
effect on FM depression and found a significant improvement after the 
treatment [31]. De Zanette et al. evaluated the effect of melatonin on the 
depression level of FM patients objectively by the assessment of serum 
brain-derived neurotrophic factor (BDNF). They observed a significant 
reduction in the serum BNDF following the melatonin intake [29]. 
3.7. The effect of melatonin on the fatigue level of FM patients 
The effect of melatonin on the fatigue level of FM patients was 
evaluated in the studies of Citera et al. and Hussain et al. [28,31]. VAS 
and fatigue subset of FIQ were used for the evaluation of fatigue, 
respectively. Citera et al. did not find a significant improvement in the 
fatigue level of patients following the melatonin administration [28], 
but the Hussain et al. did [31]. 
Table 1 
Demographic characteristics of the included studies.  










Mean age of 
patients (year) 




1 G. Citera 2000 Argentina Before and 
after 
21 19 51 3 28 
2 S.AR. 
Hussain 
2010 Iraq Placebo- 
controlled 
27 27 38.8 5 60 
3 S.A. Zanette 2014 Brazil Placebo- 
controlled 
21 19 47.4 10 42 
4 M.Y. 
Casta~noa 
2018 Spain Placebo- 
controlled 
36 33 >40 3, 6, 9, 12, 15 10  
Table 2 
Types of outcome measures’ of interest in included studies.  
ID First author Outcome of interest 
1 G. Citera Disease impact, Pain, Sleep quality, Depression, Tender Point 
count, Fatigue, Anxiety 
2 S.AR. 
Hussain 
Disease impact, Pain, Sleep quality, Stiffness, Depression, 
Fatigue, Anxiety 
3 S.A. de 
Zanette 
Disease impact, Pain, Sleep quality, depression (serum BDNF), 
Tender Point count 
4 M.Y. 
Casta~noa 
Sleep quality (objective and subjective), aMT6-s 
aMT6-s: 6-sulfatoxymelatonin; BDNF: brain-derived neurotrophic factor 
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3.8. The effect of melatonin on the anxiety level of FM patients 
The effect of melatonin on the anxiety level of FM patients was also 
assessed in the studies of Citera et al. [28] and Hussain et al. [31] using 
VAS and anxiety subset of FIQ, respectively. A significant improvement 
in anxiety level was not seen in any of these studies. 
3.9. The effect of melatonin on the stiffness level of FM patients 
The effect of melatonin on the stiffness level of FM patients was only 
assessed in the study of Hussain et al. using the stiffness subset of FIQ. A 
significant improvement in the level of stiffness was reported after the 
melatonin treatment [31]. 
3.10. The effect of melatonin on the aMT6-s urine level of FM patients 
The effect of melatonin on the urine level of aMT6-s was evaluated in 
the study Casta~noa et al. by enzyme-linked immunosorbent assay [30]. 
Compared to the placebo or washing period, significantly higher levels 
of aMT6-s was found in the first-void morning urines of FM patients 
following the administration of all melatonin concentrations, including 
3, 6, 9, 12, and 15 mg/day. 
3.11. Risk of bias report 
Selection bias was present in two out of four studies [28,30]. Per-
formance and detection bias was present in one study [28] and unclear 
in the other one [30]. Attrition bias was not detected in any of the in-
vestigations. Reporting bias was detected in one study [12]. Other biases 
were also detected in all of the studies. The detailed and overall risk of 
bias based on the authors’ judgments is presented in Figs. 2 and 3, 
respectively. 
4. Discussion 
In this study, we reviewed the interventional studies reporting the 
effect of melatonin on the treatment of FM patients. All the four studies 
included in this review reported the positive effect of melatonin on the 
improvement of FM symptoms. There was an agreement between the 
studies regarding the effect of melatonin on the disease impact, sleep 
quality, pain level, and tender point count, so that all these outcome 
measures significantly improved after melatonin administration. How-
ever, the results were not consistent regarding the effect of melatonin on 
the anxiety, fatigue, and depression level of FM patients, as some studies 
reported a significant effect, and some did not. The effect of melatonin 
treatment on the stiffness and aMT6-s level of FM patients was only 
evaluated in one study, which revealed a significant improvement in 
stiffness and a remarkable increase in urine aMT6-s level following the 
melatonin administration. 
The study of Citera et al. was the first quantitative study that re-
ported the effect of melatonin treatment in 21 FM patients and was 
published in 2000 as a pilot study with no control group. They included 
FM patients with symptom duration of at least six months. They 
excluded patients who were taking medications interfering with the 
melatonin level and could not be discontinued at least one week before 
the start of the project. After a week washing period, each patient was 
given a 3 mg oral melatonin 30 min before the sleep for four weeks. The 
mean age of the patient was 51 years, ranging from 21 to 68 years. The 
mean duration of disease was 24 months, ranging from 6 to 76 months. 
Nineteen patients completed the study. The patients and physician 
global assessment, tender point count and severity of pain at selected 
points, and sleep quality of patients were significantly improved after 
melatonin administration. Other outcome measures, including pain, 
fatigue, depression, and anxiety, were improved as well, although their 
improvement was not significant. Transient adverse effects, including 
heartburn, tremor, anxiety, and somnolence, were reported by four 
patients. They underlined the open design of the study as a confounding 
factor and suggested the evaluation of efficacy and tolerability of 
melatonin in FM patients in randomized double-blind trials [28]. 
The study of Hussain et al. was the second quantitative study that 
reported the effect of melatonin treatment in FM patients and was 
published in 2011 as a double-blind, placebo-controlled trial. This study 
evaluated the impact of melatonin alone or in combination with fluox-
etine. Although this study was introduced as a placebo-controlled trial, 
no placebo only arm was included, and the comparison was only made 
between melatonin only and melatonin þ fluoxetine group, as well as 
before and after treatment. The patients were randomly allocated into 
four study groups, including group A (20 mg/day fluoxetine þ placebo, 
24 patients), group B (5 mg/day melatonin þ placebo, 27 patients), 
group C (20 mg/day fluoxetine þ 5 mg/day melatonin, 27 patients) and 
group D (20 mg/day fluoxetine þ 5 mg/day melatonin, 23 patients). 
Fluoxetine was administered in the morning, and melatonin was 
administered at night for 60 consecutive days. The mean age of the 
patients was 38.8 years. The improvement of FIQ score was 21.5%, 
18.9%, 28.8%, and 28.9% in groups A, B, C, and D, respectively. FIQ 
improvement was more significant in fluoxetine þ melatonin groups. 
However, the dose of melatonin as an adjunct to the fluoxetine had no 
significant effect on the FIQ improvement. In the fluoxetine-only group, 
all outcome measures but fatigue, sleep, and anxiety score were signif-
icantly improved. In the melatonin only group, all the outcome measures 
except anxiety were significantly improved. In groups C and D, all the 
outcome measures were significantly improved. The results were similar 
in groups C and D [31]. 
The study of de Zanette et al. was the third quantitative study that 
reported the significance of melatonin treatment in FM patients and was 
published as a phase II, randomized, double-dummy, controlled trial in 
Fig. 2. Risk of bias summary: review authors’ judgments about each risk of bias 
item for each included study. 
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2014. Similar to the study of Hussain et al., this study compared the 
impact of melatonin alone with melatonin as an adjunct. Sixty-six pa-
tients were randomly allocated into four study groups, including: 25 
mg/day amitriptyline þ placebo, 10 mg/day melatonin þ placebo, and 
10 mg/day melatonin þ25 mg/day amitriptyline. Each group was 
comprised of 21 patients who received the allocated treatment at 
bedtime for six weeks. No placebo only group was included in this study. 
Only patients who were refractory to their current treatment were 
included. Patients were considered eligible if they had at least 50 mm on 
the 0–100 mm VAS score. Moreover, patients were allowed to remain on 
their analgesic medications. FIQ score, pain level, sleep quality, 
depression, and the number of tender points were improved significantly 
in all groups. The level of improvement was more in the combined group 
than the melatonin or amitriptyline alone groups. They pointed out the 
external validity issue as the main limitation of their study [29]. 
Allowing the patients to remain on their analgesic medication could be 
regarded as the other limitation of this study. 
The study of Casta~no et al. is the fourth and last quantitative study 
that reported the significance of melatonin treatment in 33 FM patients. 
This study was performed in 2018 with a longitudinal placebo- 
controlled design including five 10-day melatonin treatment periods, 
separated by four 10-day washout periods. Melatonin doses of 3, 6, 9, 
12, and 15 mg were administered at melatonin periods, consecutively. 
All doses were taken 30 min before sleep for ten days. During the 
washout periods, the placebo was substituted with melatonin. The 
objective and subjective assessment of sleep quality was the primary 
outcome measure of interest. The mean age of the patients was not re-
ported in this study. Regarding the objective sleep quality assessment, 
the intake of 6, 12, and 15 mg/day melatonin significantly reduced the 
sleep latency concerning basal and placebo conditions. The 12 and 
15 mg/day melatonin also significantly improved sleep efficiency, 
immobility, actual sleep time, and assume sleep. Doses of 6, 9, 12, and 
15 mg/day of melatonin significantly improved subjective sleep quality. 
In this respect, the dose of 12 mg/day of melatonin revealed the most 
significant reduction. They suggested melatonin as an adjunct therapy 
for the management of FM [30]. 
A review of the literature reveals a considerable heterogeneity be-
tween the available studies on the role of melatonin in the treatment of 
FM patients. This heterogeneity is seen in a variety of aspects, particu-
larly in the design of the study. In the majority of included studies (three 
out of four), no placebo group was available to evaluate the effect of 
melatonin in comparison with no treatment group. The only controlled 
investigation was the study of Casta~no et al. that used placebo-washout 
control in a cross-over design [30]. Therefore, more placebo-controlled 
trials are required to reach a consensus regarding the impact of 
melatonin in FM patients. 
A remarkable discrepancy was also observed between the dosages of 
melatonin in different studies, ranging from 3 mg/day to 15 mg/day. 
Interestingly, while the dose of 3 mg/day of melatonin was reported to 
be efficacious in the treatment of FM symptoms in the study of Citera 
et al. [28], it showed no significant effect on the study of Casta~no et al. 
[30]. Besides, the duration of melatonin administration was consider-
ably heterogeneous, ranging from 10 to 60 days. Ferracioli-Oda et al. in 
a meta-analysis, reviewed the impact of melatonin in the treatment of 
primary sleep disorders. Based on their results, longer duration and 
higher doses of melatonin administration revealed more significant ef-
fects on decreasing sleep latency as well as increasing total sleep time 
[32]. However, the systematic review of Vural et al. on the optimal 
dosages for melatonin therapy in older adults suggested the lowest 
possible dose of immediate-release melatonin to best mimic the normal 
physiological circadian rhythm and to prevent prolonged 
supra-physiological circulating levels [33]. Hence, the optimized dura-
tion and dosage of melatonin administration in FM patients remain to be 
identified. 
The demographic and clinical characteristics of patients in the 
included studies were also not comparable. Although nearly all the 
included patients were females, the age range of the patients was wide, 
so that FM patients with age ranging from 18 to 65 years were included. 
While in the majority of studies, a considerable number of patients were 
below the age of 40 years, Casta~no et al. only included patients with the 
age of over 40 years. This difference could also be regarded as a source of 
heterogeneity, as melatonin levels gradually decline over the life-span, 
and older patients may require a higher dosage [34,35]. Casta~no et al. 
only included patients with a total FIQ score of >70. The fibromyalgia 
impact was not considered in the other three investigations. However, 
the impact of the disease is acknowledged as a factor in determining the 
dosage of melatonin [35,36]. 
Although the results of all four quantitative studies revealed the 
beneficial effects of melatonin administration in the treatment of FM 
symptoms, the present review demonstrates a substantial heterogeneity 
in the variety of aspects of the studies such as study design, inclusion and 
exclusion criteria, dosage and duration of melatonin administration, and 
patients’ characteristics. Even so, melatonin could still be regarded as a 
valuable treatment of choice in FM patients, as the other available 
pharmacological treatment of fibromyalgia are associated with a variety 
of adverse effect and limited benefits. For example, duloxetine, as one of 
the main pharmacological treatment in FM patients, is associated with a 
high rate of discontinuation and adverse events including dry mouth, 
vomiting, decreased appetite, constipation, insomnia, dizziness, fatigue, 
somnolence [37,38]. 
Fig. 3. Risk of bias graph: review authors’ judgments about each risk of bias item presented as percentages across all included studies.  
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The present systematic review was not without weakness. The main 
limitation of this study was the very limited number of studies that did 
not allow performing a meta-analysis. Besides, Gray literature was not 
searched in this review due to a lack of access. Considering the signifi-
cant amount of heterogeneity between the available studies, the current 
review urges the need to perform more high-quality controlled clinical 
trials on the effect of melatonin in FM patients. 
5. Conclusion 
Melatonin treatment has several positive effects on FM patients, 
including the improvement of sleep quality, pain, and disease impact. By 
contrast to conventional pharmacological agents such as duloxetine, no 
major adverse events were reported following the melatonin consump-
tion. Therefore, melatonin could be regarded as a safe and efficacious 
treatment in FM. Nevertheless, the significant level of heterogeneity 
between the available studies urges the need to perform further high- 
quality investigations in this respect. 
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